| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 352.72 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).
Methods: Retrospective evaluation of patients with mCRPC treated with AA.
Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001).
Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.
Description
© Cecilia Melo Alvim. This work is licensed under the Creative Commons Attribution4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords
Abiraterone acetate Metastatic castration-resistant prostate cancer Prostate-specific antigen response
Pedagogical Context
Citation
Future Sci OA. 2019 Dec 12;6(2):FSO436
Publisher
Future Science Ltd.